プログレッシブ HM に対する IOP 低下の影響 (PHM)
医学的に眼圧を下げることが進行性近視に及ぼす影響
Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Myopia has emerged as a major health issue in east Asia, especially the sight-threatening complications associated with high myopia (HM). Complication of HM can be associated with significant ocular morbidities including maculopathy, retinal detachment, and glaucoma.
Previous studies have shown that adult patients with HM have sustained growth of the axial length (AL), which is a risk factor for the progression of pathological myopia and thus may further affect the visual function , so how to slow down the sustained growth of the AL in adult patients with HM has become an urgent clinical problem. Previous studies have shown that IOP-lowering treatment is a protective factor for the growth of the AL in HM , and the results of animal experiments have further shown that medically IOP-lowering treatment can significantly slow down the AL lengthening and refractive changes in the guinea pig model of myopia. On this basis, the investigators proposed in a previous article that medically IOP-lowering treatment may slow down the growth of AL by three pathways related to the sclera and choroid: for the sclera, IOP-lowering treatment may reduce the scleral distending force, slow down the rate of scleral distension, and inhibit the activation of scleral fibroblasts to reduce scleral remodeling; for the choroid, IOP-lowering treatment may increase choroidal blood perfusion and for the choroid, hypotensive treatment can increase choroidal perfusion and thus reduce scleral remodeling due to scleral hypoxia. A previous retrospective study conducted by the investigators also shows that medically IOP-lowering treatment could control the progression of AL in HM, but there is still a lack of evidence from relevant robust randomized controlled clinical trials (RCT).
The investigators propose to conduct a RCT to evaluate whether medically IOP-lowering therapy is effective in controlling the progression of AL in HM. Secondly, this study also aims to provide data to evaluate IOP-lowering treatment effects on the incidence of changes in the visual field (VF), optic nerve head morphology including the retinal nerve fiber layer (RNFL), and retinal ganglion cell-inner plexiform layer (GC-IPL) loss, progression of myopic maculopathy, loss in visual function and change in quality of life. The outcomes of this study may provide a strong basis for treatment recommendations to control the progression of high myopic eyes, and to provide high-quality clinical research evidence for international clinical guidelines on myopia.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Informed consent given, and consent form signed.
- Age between 18 and 65 years.
- Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm.
- Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months.
- IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry .
- Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination.
Exclusion Criteria:
- Allergic to any kind of IOP-lowering therapy.
- Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc.
- Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis.
- Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye.
- Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery.
- Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment.
- Pregnant or lactating women, or those who plan to have children during the follow-up period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Intervention arm
medical reduction of IOP by eyedrops |
IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment. |
|
介入なし:control arm
follow up without medication |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 12 months
時間枠:12 months
|
The cumulative change in AL from baseline to 12 months. |
12 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 24 months
時間枠:24 months
|
The cumulative change in AL from baseline to 24 months divided by 2 years. |
24 months
|
|
Annualized change in axial length (AL) from baseline to 36 months
時間枠:36 months
|
The cumulative change in AL from baseline to 36 months divided by 3 years. |
36 months
|
|
Change in spherical equivalent (SE) from baseline
時間枠:12, 24, and 36 months
|
Change in spherical equivalent refraction (SE) from baseline. |
12, 24, and 36 months
|
|
Change in intraocular pressure (IOP) from baseline
時間枠:12, 24, and 36 months
|
Change in intraocular pressure (IOP) from baseline |
12, 24, and 36 months
|
|
Change in choroidal thickness (ChT) from baseline
時間枠:12, 24, and 36 months
|
Change in subfoveal choroidal thickness (ChT) measured by OCT from baseline. |
12, 24, and 36 months
|
|
Change in visual field (VF) parameters and incidence/progression of VF defects
時間枠:12, 24, and 36 months
|
Change in Humphrey 24-2 mean deviation (MD) and pattern standard deviation (PSD) from baseline, and the incidence and progression of visual field defects |
12, 24, and 36 months
|
|
Change in retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness
時間枠:12, 24, and 36 months
|
Change in peripapillary RNFL and macular GCIPL thickness measured by OCT from baseline |
12, 24, and 36 months
|
|
Change in retinal and choroidal vascular parameters measured by OCTA
時間枠:12, 24, and 36 months
|
Change in vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), and choriocapillaris (CC) flow metrics from baseline |
12, 24, and 36 months
|
|
Incidence of optic nerve head morphological changes
時間枠:12, 24, and 36 months
|
Incidence of morphological changes based on stereoscopic fundus photography, including increased cup-to-disc ratio, neuroretinal rim notching, wedge-shaped RNFL defects, or disc hemorrhage. |
12, 24, and 36 months
|
|
Incidence and progression of myopic maculopathy (MMD)
時間枠:12, 24, and 36 months
|
The incidence and progression rate of myopic maculopathy classified by the international photographic classification system. |
12, 24, and 36 months
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
時間枠:1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
The incidence, severity, and relationship to study medication of all adverse events (AEs) and serious adverse events (SAEs) |
1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Xiulan Zhang, MD, PhD、Sun Yat-sen University
出版物と役立つリンク
一般刊行物
- Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9.
- Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1999 May;127(5):625-6. No abstract available.
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
- Jiang J, Lin T, Lin F, Kong K, Wang P, Song Y, Zhou F, Wang Z, Jin L, Liu Y, Gao X, Chen J, Chen M, Lam DSC, Jonas JB, Chen S, Zhang X; Glaucoma Suspects with High Myopia Study Group. Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial. BMJ Open. 2024 Jun 5;14(6):e084068. doi: 10.1136/bmjopen-2024-084068.
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。